Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?
Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?
复制标题
通过 CT 成像早期评估舒尼替尼治疗晚期胃肠胰神经内分泌肿瘤：RECIST 1.1 或 Choi 标准？
DOI：
10.1186/s12885-017-3150-7
复制
发表时间：
2017-02-23
期刊：
影响因子：
3.8
通讯作者：
Feng ST
中科院分区：
文献类型：
--
作者：
Luo Y;Chen J;Huang K;Lin Y;Chen M;Xu L;Li ZP;Feng ST
背景本研究的目的是评估和比较疗效评价标准在实体瘤版本1.1（RECIST 1.1）和Choi标准在评估晚期胃肠胰腺神经内分泌肿瘤（GEP-NEN）与舒尼替尼治疗的早期反应。对所有患者进行治疗前和治疗后CT扫描（平扫、双相增强CT扫描）。测量并记录每例患者从治疗前到治疗后1.4-3.1个月的靶肿瘤大小和密度的变化。使用RECIST 1.1和Choi标准确定肿瘤缓解。肿瘤进展的时间（TTP）为每个患者进行了测量和组间比较使用Kaplan-Meier method.ResultsAmong 18例患者，4（22%）表现出部分反应（PR），9（50%）表现出稳定的疾病（SD），和5（28%）经历了疾病进展（PD），使用RECIST 1.1。然而，根据Choi标准，8例（44%）患者显示PR，4例（22%）显示SD，6例（33%）出现PD。根据RECIST1.1，PR、SD和PD组的中位TTP分别为16.6、10.8和2.3个月。PR组的TTP显著长于PD组（P= 0.007），但与SD组相比无显著性差异（P= 0.131）。根据Choi标准，PR、SD和PD组的中位TTP分别为10.8和2.3个月。PR组TTP明显长于SD组（P= 0.026）和PD组（P< 0.001）。结论Choi标准在评价舒尼替尼治疗晚期GEP-NEN的早期疗效方面比RECIST 1.1标准更敏感、更准确。
BackgroundThe aim of this study was to assess and compare the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and the Choi criteria in evaluating the early response of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) treated with sunitinib.MethodsEighteen patients with pathologically proven advanced GEP-NENs treated with sunitinib were enrolled in the study. Pre- and post-treatment CT scans (plain, biphasic enhanced CT scan) were performed on all patients. Changes in the target tumor size and density from pre-treatment to 1.4–3.1 months after treatment were measured and recorded for each patient. Tumor responses were identified using RECIST 1.1 and Choi criteria. The time to tumor progression (TTP) for each patient was measured and compared between groups using the Kaplan-Meier method.ResultsAmong the 18 patients, 4 (22%) exhibited a partial response (PR), 9 (50%) exhibited stable disease (SD), and 5 (28%) experienced progressive disease (PD), using RECIST 1.1. However, based on the Choi criteria, 8 (44%) patients exhibited a PR, 4 (22%) exhibited SD, and 6 (33%) experienced PD. According to RECIST 1.1, the median TTP of PR, SD and PD group were 16.6, 10.8 and 2.3 months, respectively. The TTP of the PR group was significantly longer than that of the PD group (P= 0.007) but insignificant when compared to the SD group (P= 0.131). According to Choi criteria, the median TTP of PR, SD and PD group were not reached, 10.8 and 2.3 months, respectively. The TTP of the PR group was significantly longer than that of the SD (P= 0.026) and PD groups (P< 0.001).ConclusionThe Choi criteria appear to be more sensitive and more precise than RECIST 1.1 in assessing the early response of advanced GEP-NENs treated with sunitinib.